Foghorn Therapeutics (FHTX) Asset Writedowns and Impairment (2024 - 2025)
Foghorn Therapeutics (FHTX) recorded quarterly Asset Writedowns and Impairment of $5.9 million in Q4 2025, up 146.62% quarter-over-quarter from $2.4 million in Q2 2024.
Foghorn Therapeutics (FHTX) Asset Writedowns and Impairment (2024 - 2025) Analysis & Trends
Foghorn Therapeutics' Asset Writedowns and Impairment history runs 2 years deep, the most recent figure standing at $5.9 million for Q4 2025.
- In Q4 2025, Asset Writedowns and Impairment changed N/A year-over-year to $5.9 million; the TTM figure through Dec 2025 stood at $5.9 million (up 146.62% YoY), while the FY2025 annual figure was $5.9 million, up 146.62% from the prior year.
- Asset Writedowns and Impairment was $5.9 million for Q4 2025 at Foghorn Therapeutics, up from $2.4 million in the prior quarter.
- In the past five years, Asset Writedowns and Impairment ranged from a high of $5.9 million in Q4 2025 to a low of $2.4 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Foghorn Therapeutics | 282.33 Mn | 193.42 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.91 Mn |
| Dec 31, 2025 | 5.91 Mn |
| Jun 30, 2024 | 2.40 Mn |
| Jun 30, 2024 | 2.40 Mn |